𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man

✍ Scribed by G. Flesch; P. Müller; P. Lloyd

Publisher
Springer
Year
1997
Tongue
English
Weight
168 KB
Volume
52
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The pharmacokinetics and metabolism of C
The pharmacokinetics and metabolism of CP-191,166, an angiotensin II receptor antagonist, in rats and dogs
✍ Mary C. Allen; Mark R. Nocerini; Wesley W. Day 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

166 is an orally active, non-peptide angiotensin II (AII) receptor antagonist developed for the treatment of hypertension and congestive heart failure (CHF). In this study, the intravenous (iv) and oral (po) single dose pharmacokinetics (PK), oral multiple dose PK and P450-mediated metabolism of 16

Effects of cimetidine on pharmacokinetic
Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist
✍ M. R. Goldberg; M. W. Lo; T. E. Bradstreet; M. A. Ritter; P. Högland 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 512 KB

This was a 2-period randomized, crossover study in 8 healthy males to determine the effects of cimetidine (400 mg q.i.d. for 6 days) on the pharmacokinetics and pharmacodynamic effects of the angiotensin II receptor antagonist, losartan (100 mg). Cimetidine increased the AUC for losartan 18% without

The pharmacokinetics and metabolism of D
The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs
✍ Y. N. Wong; K. A. Holm; D. L. Burcham; S.-M. Huang; C. Y. Quon 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB 👁 1 views

DuP 532, 2-propy1-4-pentafluoroethyl-l-[ [2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylJ imidazole-5-carboxylic acid, is an orally active, non-peptide angiotensin I1 (AII) receptor antagonist. DuP 532 is more potent and longer acting than losartan, another A11 receptor antagonist currently undergoing ph